Albireo Pharma Executives

ALBODelisted Stock  USD 44.15  0.75  1.67%   
Albireo Pharma employes about 130 people. The company is managed by 25 executives with a total tenure of roughly 121 years, averaging almost 4.0 years of service per executive having 5.2 employees per reported executive. Analysis of Albireo Pharma management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Albireo Pharma future performance.
Check out Trending Equities.
Ronald Cooper  CEO
President CEO, Director
David Chiswell  Chairman
Chairman of the Board
Peter Zorn  President
Senior Vice President - Corporate Development, General Counsel and Secretary

Albireo Pharma Return on Sales


Albireo Pharma Management Team Effectiveness

Albireo Pharma has return on total asset (ROA) of (0.2494) % which means that it has lost $0.2494 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.9308) %, meaning that it created substantial loss on money invested by shareholders. Albireo Pharma management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. As of 26th of March 2023, Return on Invested Capital is likely to grow to 22.38, while Return on Investment is likely to drop (81.40) . Albireo Pharma Tangible Assets Book Value per Share are very stable at the moment as compared to the past year. Albireo Pharma reported last year Tangible Assets Book Value per Share of 13.34. As of 26th of March 2023, Average Assets is likely to grow to about 331.2 M, while Goodwill and Intangible Assets are likely to drop about 17.2 M.
As of 26th of March 2023, Weighted Average Shares is likely to grow to about 23.8 M. Also, Weighted Average Shares Diluted is likely to grow to about 23.8 M

Albireo Pharma Workforce Comparison

Albireo Pharma is number one stock in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 123,863. Albireo Pharma adds roughly 130 in number of employees claiming only tiny portion of equities under Health Care industry.

Albireo Pharma Profit Margins

The company has Profit Margin (PM) of (2.29) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.15.

Albireo Pharma Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Albireo Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Albireo Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Albireo Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Albireo Pharma Notable Stakeholders

An Albireo Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Albireo Pharma often face trade-offs trying to please all of them. Albireo Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Albireo Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ronald CooperPresident CEO, DirectorProfile
David ChiswellChairman of the BoardProfile
Peter ZornSenior Vice President - Corporate Development, General Counsel and SecretaryProfile
Thomas SheaCFO, TreasurerProfile
Simon HarfordCFO, TreasurerProfile
Brian PereiraIndependent DirectorProfile
Davey ScoonDirectorProfile
Stephanie OkeyDirectorProfile
Anne KlibanskiDirectorProfile
Denise ScotsKnightDirectorProfile
Michael GutchDirectorProfile
Roger JeffsDirectorProfile
Heather PrestonDirectorProfile
Julia BrownIndependent DirectorProfile
Michelle GrahamChief OfficerProfile
Kristina TorfgardVP HeadProfile
Pamela MPHChief OfficerProfile
Jason DuncanGen OfficerProfile
Pamela StephensonChief Commercial OfficerProfile
Joan ConnollyChief OfficerProfile
Martha CarterChief Regulatory OfficerProfile
Jan MattssonMD OfficerProfile
Patrick HornChief Medical OfficerProfile
Paresh SoniChief Medical OfficerProfile
PerGoran GillbergCoFounder DevelProfile

About Albireo Pharma Management Performance

The success or failure of an entity such as Albireo Pharma often depends on how effective the management is. Albireo Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Albireo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Albireo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2023
Return on Investment(75.44) (81.40) 
Return on Average Assets(0.15) (0.15) 
Return on Average Equity(0.25) (0.27) 
Return on Invested Capital 20.74  22.38 
Return on Sales(0.57) (0.62) 
The data published in Albireo Pharma's official financial statements usually reflect Albireo Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Albireo Pharma. For example, before you start analyzing numbers published by Albireo accountants, it's critical to develop an understanding of what Albireo Pharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Albireo Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Albireo Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Albireo Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Albireo Pharma. Please utilize our Beneish M Score to check the likelihood of Albireo Pharma's management to manipulate its earnings.

Albireo Pharma Workforce Analysis

Traditionally, organizations such as Albireo Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Albireo Pharma within its industry.

Albireo Pharma Manpower Efficiency

Return on Albireo Pharma Manpower

Revenue Per Employee360.5K
Revenue Per Executive1.6M
Net Loss Per Employee324.8K
Net Loss Per Executive1.4M
Working Capital Per Employee205.9K
Working Capital Per Executive1.1M
Today, most investors in Albireo Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Albireo Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Albireo Pharma per employee as a starting point in their analysis.

Net Income Per Employee


Albireo Pharma Net Income Per Employee is very stable at the moment as compared to the past year. Albireo Pharma reported last year Net Income Per Employee of (301,034)

Revenue Per Employee


Albireo Pharma Revenue Per Employee is very stable at the moment as compared to the past year. Albireo Pharma reported last year Revenue Per Employee of 358,968
Check out Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Transaction History
View history of all your transactions and understand their impact on performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.